Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High Dose Drug Device
- Development stage
- Unknown
- Lead developer
- MediPrint Ophthalmics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
High Dose Drug Device was an investigational **sustained-release bimatoprost ophthalmic drug-delivery device** developed by Vistakon Pharmaceuticals for open-angle glaucoma and ocular hypertension. The Phase 2 program evaluated ocular safety and intraocular-pressure lowering using a high-dose bimatoprost-releasing device, described in the provided trial context as a contact-lens delivery platform. Bimatoprost is a synthetic prostamide and prostaglandin analog that lowers intraocular pressure by increasing aqueous-humor outflow. The program was completed at Phase 2 and has no evident active subsequent development. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT01016691))
- Other names
- High Dose Device
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on High Dose Drug Device.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High Dose Drug Device.